Navigation Links
BioInformatics LLC Multi-Sponsor Market Report – In-depth Exploration of the U.S. Market for Biosimilar Drugs

Arlington, VA (PRWEB) February 21, 2013

The delivery of more cost-effective healthcare has become a worldwide challenge as the costs associated with healthcare continue to increase, driven by changing demographics, societal expectations and advances in medical technology. The introduction of alternative versions of biologic products, also known as biosimilars, into the United States market has been gaining increasing visibility as patents for many agents are nearing expiration and as the FDA moves closer to establishing a regulatory pathway for these agents. For these reasons, BioInformatics LLC is opening sponsorship opportunities for an in-depth report in this space: Manufacture of Biosimilar Drugs for the U.S. Market: Defining the Market Opportunity for Life Science Suppliers.

As scientific and analytical instrument manufactures seek to explore new markets to offset slower growth and reduced funding in academic research, attention turns to the potential for revenues generated by the pending authorization for pharmaceutical and biopharmaceutical companies to move forward with the development and commercialization of biosimilar drugs in the U.S.

The process is complicated, and the onus is on the drug manufacturers to prove that the biosimilar drugs have a similar structure and function as the original branded drugs. As with a generic small-molecule drug, biosimilars will ostensibly be less costly for the consumer and therefore enjoy a sizable demand. However, long before this nascent family of drugs can reach the market, biopharmaceutical companies will be required to ramp up their capacity to conduct the FDA-required analysis.

Or will they? Are labs going to need new instruments, or will they be able to conduct this research with their currently installed equipment? Will new features be required to achieve the biophysical characteristics and biological function of the reference standard biological drug? Which molecules will be targeted? Will new drugs be developed that go beyond the efficacy of the branded version?

These are questions that suppliers are asking and that will be addressed in the syndicated report: Manufacture of Biosimilar Drugs for the U.S. Market: Defining the Market Opportunity for Life Science Suppliers. Comprised of 25 interviews from U.S. pharmaceutical/CRO companies and 25 interviews with EU pharmaceutical/CRO companies—to include both R&D and regulatory personnel—this report will be an in-depth exploration of what the decision-makers are saying about what’s on the near horizon for biosimilar drug development.

The report is scheduled to release on May 31, 2013. The deadline to become a sponsor for this research is March 8, 2013. Click here for a more complete description of the report.


BioInformatics LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 71,000 life scientists, we have supported more than 500 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Global Bioinformatics Industry
2. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
3. BioInformatics LLC New Product Launch – RateMyProduct, a Quick Turnaround Product Assessment Tool for Life Science Suppliers
4. BioInformatics LLC New Market Report – Opportunities for New Players in the Growing Stem Cell Market
5. BioInformatics LLC Webcast – The Life Science Product Manger’s Toolkit
6. BioInformatics LLC New Market Report – Best Practices Guide for Advertising to Life Scientists
7. Japan Bioinformatics Announces the Release of their Simbiot® Time Course Analysis ‘How-To’ Guide
8. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
9. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
10. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
11. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 Frost & Sullivan ... This program addresses ways companies can innovate and ... --> ... --> ... as well as the disrupting factors altering the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Park Systems , world ... scanning ion conductance microscopy module to Park NX10 that is the only product ... SICM benefits virtually all materials characterization that require measurements in liquid such as ...
(Date:12/1/2015)... December 1, 2015 Dr. Harry Lander , President of ... as Chief Science Officer and recruits five distinguished ... Lander , President of Regen, expands his role to include ... recruits five distinguished scientists to join advisory team ... expands his role to include serving as ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global ... and development stages of a new closed system for isolating adipose-derived stem cells. The ... vascular fraction (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):